eligibility_summary
Eligibility: Women with histologically confirmed high-grade serous ovarian/primary peritoneal/fallopian tube cancer, platinum-resistant (progression ≤6 mo after last platinum, if only 1 prior line, >1–≤6 mo after ≥4 cycles), 1–3 prior lines, RECIST-measurable progression, tumor tissue for FRα testing, ECOG 0–1. Exclude: non-HGS histology, platinum-refractory, abnormal PFTs, ILD/pneumonitis, significant effusions, organ dysfunction, severe mAb/eribulin/steroid allergy, chemo contraindication.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 randomized trial in platinum‑resistant high‑grade serous ovarian/primary peritoneal/fallopian tube cancer comparing MORAb‑202 (farletuzumab ecteribulin) vs investigator’s choice chemotherapy (paclitaxel, pegylated liposomal doxorubicin [PLD], or topotecan). MORAb‑202: antibody‑drug conjugate (ADC), farletuzumab (anti–folate receptor‑alpha [FRα] IgG) delivers eribulin (microtubule dynamics inhibitor) to FRα‑expressing tumor cells. Mechanism: FRα binding → receptor‑mediated endocytosis → intracellular eribulin release → microtubule disruption, G2/M arrest, apoptosis, potential bystander effect. Targets: FRα‑overexpressing epithelial ovarian cancer cells, microtubules/cell‑cycle machinery. Comparator MoAs: paclitaxel (taxane, β‑tubulin stabilization, blocks depolymerization), PLD (anthracycline, DNA intercalation, topoisomerase II inhibition, ROS, liposomal delivery), topotecan (topoisomerase I inhibitor). Pathways: FRα, microtubule dynamics, DNA replication/repair.